Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Key facts

Sponsor

Tyra Biosciences, Inc

Principal Investigator

Doug Warner, MD

Tyra Biosciences, Inc

Intervention

TYRA-430(drug)

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2028

Study locations (16)

• USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
• UCSF Medical Center at Mount Zion, San Francisco, California, United States
• Stanford Cancer Institute, Stanford, California, United States
• The University of Kansas Medical Center, Westwood, Kansas, United States
• John Hopkins University, Baltimore, Maryland, United States
• Mass General Cancer Center, Boston, Massachusetts, United States
• Karmanos Cancer Institute, Detroit, Michigan, United States
• Columbia University Irving Medical Center, New York, New York, United States
• Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
• University Health Network Princess Margaret Cancer Center, Toronto, Ontario, Canada
• Asan Medical Center, Seoul, South Korea
• Samsung Medical Center, Seoul, South Korea
• Seoul National University Hospital, Seoul, South Korea
• Severance Hospital, Yonsei University Health System, Seoul, South Korea
• National Taiwan University Hospital, Taipei, Taiwan
• +1 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →